Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tyra BiosciencesTYRA -4.21%28 Net Cash per Share is $5.43 as of Jun. 2026, which is 130% above its 10-year median of 2.36. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 757 Biotechnology companies, Tyra Biosciences ranks better than 53.37% on this metric.
Tyra Biosciences (NAS:TYRA) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Tyra Biosciences Net Cash per Share Related Terms
Tyra Biosciences Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Tyra Biosciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYRA vs STOK, SNDX, FTRE: Net Cash per Share Comparison
For the Biotechnology subindustry, Tyra Biosciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyra Biosciences Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Tyra Biosciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Tyra Biosciences's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tyra Biosciences (TYRA) has a Net Cash per Share of $5.43 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Tyra Biosciences and its competitors. This is 130% above median its historical median of 2.36. Over the past decade, Tyra Biosciences' Net Cash per Share has ranged from 1.12 to 6.34. According to the industry distribution chart, Tyra Biosciences ranks #353 out of 757 companies in the Biotechnology industry, placing it in the top 46.6%.
Is Tyra Biosciences' Net Cash per Share too high?
Tyra Biosciences' current Net Cash per Share of $5.43 is 130% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 1.12 to a high of 6.34. The Biotechnology industry median Net Cash per Share is 5.17. Tyra Biosciences' value of $5.43 is 5% above this industry median. Based on the distribution chart, Tyra Biosciences ranks #353 out of 757 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Net Cash per Share compare to STOK and SNDX?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #353 out of 757 companies for Net Cash per Share. This puts Tyra Biosciences in the upper half of its industry. The industry median Net Cash per Share is 5.17. Tyra Biosciences' value of $5.43 is 5% above this benchmark. Historically, Tyra Biosciences' own Net Cash per Share has ranged from 1.12 to 6.34 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 5.17, Tyra Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.17, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tyra Biosciences's current Net Cash per Share of $5.43 is 5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Tyra Biosciences and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tyra Biosciences's current Net Cash per Share is $5.43, which is 130% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Net Cash per Share of $5.43. The current Net Cash per Share is $5.43, which is 130% above median its 10-year median of 2.36 and 5% above the Biotechnology industry median of 5.17. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Net Cash per Share is $5.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score
Get the complete analysis for TYRA
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYRA has been successfully added to your 
